The tweet was deleted by the author.
But we saved everything 🙂.
Candel Therapeutics, Inc. is placing increased emphasis on targeted therapies within the oncology sector, as outlined by the company’s CEO, Paul Peter Tak, in a recent feature for PharmaTechFocus.
Tak discussed where viral immunotherapies fit into the evolving landscape, pointing to a growing integration of these innovative treatments within cancer care. The company continues to evaluate opportunities within immunotherapy and oncology, indicating a broader industry tilt toward precision medicine approaches.
Candel has previously outlined plans to present key phase 3 trial follow-up data for its CAN-2409 therapy in prostate cancer at AUA2026, according to a company statement. The company is also advancing viral immunotherapies across prostate, lung, and brain cancer programs, as detailed in its latest research updates. These efforts form part of Candel’s continuing focus on targeted oncology solutions.